Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Arizona State Retirement System

Arizona State Retirement System grew its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report) by 2.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,211 shares of the company’s stock after acquiring an additional 541 shares during the period. Arizona State Retirement System’s holdings in Apellis Pharmaceuticals were worth $883,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. First Horizon Advisors Inc. raised its position in Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after acquiring an additional 265 shares in the last quarter. National Bank of Canada FI acquired a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter worth approximately $33,000. Stephens Consulting LLC bought a new stake in Apellis Pharmaceuticals in the third quarter valued at about $38,000. Focused Wealth Management Inc acquired a new position in Apellis Pharmaceuticals in the second quarter worth about $45,000. Finally, US Bancorp DE lifted its stake in Apellis Pharmaceuticals by 391.2% during the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after purchasing an additional 884 shares during the period. 90.43% of the stock is currently owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $67.31 on Wednesday. The stock has a market cap of $7.98 billion, a PE ratio of -12.82 and a beta of 0.93. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.76 and a current ratio of 4.29. The firm has a 50-day moving average of $62.39 and a 200-day moving average of $48.54. Apellis Pharmaceuticals, Inc. has a 52-week low of $19.83 and a 52-week high of $94.75.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on APLS. Citigroup reduced their target price on shares of Apellis Pharmaceuticals from $70.00 to $67.00 and set a “buy” rating on the stock in a research note on Friday, December 15th. Mizuho began coverage on Apellis Pharmaceuticals in a report on Thursday, November 2nd. They set a “neutral” rating and a $42.00 price objective for the company. Bank of America raised Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $52.00 to $85.00 in a research note on Tuesday, December 5th. Raymond James increased their price target on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a “strong-buy” rating in a research report on Thursday, January 11th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $74.73.

Read Our Latest Stock Analysis on APLS

Insider Buying and Selling

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 2,235 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total transaction of $149,320.35. Following the transaction, the chief financial officer now owns 99,226 shares in the company, valued at approximately $6,629,289.06. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CFO Timothy Eugene Sullivan sold 2,235 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total transaction of $149,320.35. Following the completion of the transaction, the chief financial officer now owns 99,226 shares of the company’s stock, valued at approximately $6,629,289.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO James George Chopas sold 864 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $66.81, for a total transaction of $57,723.84. Following the completion of the sale, the chief accounting officer now owns 40,128 shares in the company, valued at $2,680,951.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,826 shares of company stock valued at $4,301,015. Insiders own 7.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

(Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).

Featured Stories

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report).

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.